AZ enrolls first patient in Brilinta stroke trial
Brilinta (ticagrelor) is approved for the treatment of acute coronary syndromes and prevention of further coronary events in patients at high-risk following a heart attack.
Read More
Tag: Parthenon
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
